Akeso Inc. has announced that its first bispecific Antibody-Drug Conjugate $(ADC)$, AK146D1, has received regulatory approval to commence clinical trials from the U.S. Food and Drug Administration (FDA), Australia's Therapeutic Goods Administration $(TGA)$, and China's National Medical Products Administration (NMPA). This marks a significant milestone for Akeso, as AK146D1 targets both Trop2 and Nectin4, representing a key component of the company's "IO+ADC" 2.0 strategy aimed at advancing cancer therapies. The approval allows Akeso to proceed with its Phase Ia clinical trial, with the first patient already successfully enrolled.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。